Allena Pharmaceuticals — Investor Presentation (March 2019)
26 slides from Allena Pharmaceuticals's investor presentation, Mar 13, 2019
Slide 1: Bringing First-in-Class Oral Enzyme Therapeutics to Patients with Rare and Severe Metabolic and Kidney Disorders
Bringing First-in-Class Oral Enzyme Therapeutics to Patients with Rare and Severe Metabolic and Kidney Disorders March 2019 Exhibit 99.1
Slide 2: Forward-Looking Statements
Allena Pharmaceuticals, Inc. These slides, and any accompanying presentation, contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue
Slide 3: Highlights – Pioneering Oral Enzyme Therapeutic Platform
Highlights – Pioneering Oral Enzyme Therapeutic Platform Significant Unmet Need in Oxalate and Urate Disorders Focused on rare and severe metabolic disorders that can cause kidney stones, damage the kidney, and potentially lead to CKD and ESRD No approved oxalate therapies; potential untapped multi-
Slide 4: Allena Recently Achieved FDA Alignment on Strategy for Accelerated Approval Pathway
Post-Approval Clinical Benefit Phase Allena Recently Achieved FDA Alignment on Strategy for Accelerated Approval Pathway for Reloxaliase and Design of URIROX-2 1° efficacy endpoint: Percent change from baseline in 24h UOx excretion during Weeks 1-4 2° efficacy endpoint: Proportion of patients with ≥
Slide 5: Allena's Pipeline: First-in-Class Therapeutic Strategy for Oxalate and Urate Disorders
Product Indication Discovery Pre-Clinical Phase 1 Phase 2 Phase 3 Next Milestone Commercial Rights Reloxaliase Enteric hyperoxaluria 2H19: Topline data URIROX-1 Worldwide Systemic oxalosis* 1H19: Interim data Worldwide Primary hyperoxaluria* (Orphan Designation) 1H19: Interim data Worldwide Pediatri
Slide 6: First-in-Class Therapeutic Strategy
First-in-Class Therapeutic Strategy Expertise and Proprietary Technological Approach in Enzyme Therapeutics Enables First-in-Class Therapeutic Strategy for Oxalate and Urate Disorders Pioneering Expertise in Oral Enzyme Therapeutics Design, formulation, and delivery of non-absorbed and stable enzyme
Slide 7: Hyperoxaluria is Characterized by Markedly Elevated Urinary Oxalate Levels
Hyperoxaluria is Characterized by Markedly Elevated Urinary Oxalate Levels Source: Illustration adapted from Coe, Fred. “Control of Urine Oxalate Excretion.” Kidneystones.uchicago.edu. University of Chicago, kidneystones.uchicago.edu/control-of-urine-oxalate-excretion . March 2017. Fecal Excretion G
Slide 8: Enteric Hyperoxaluria Patients Are a High Risk Population in Need of Treatment
Enteric Hyperoxaluria Patients Are a High Risk Population Who Are Identifiable by Physicians and in Need of Treatment There are no FDA approved pharmacological therapies to treat any form of hyperoxaluria Enteric GI malabsorptive conditions include: gastric bypass surgery, Crohn’s disease, ulcerativ
Slide 9: Risk of Renal Complications Rises with Higher Urinary Oxalate Levels
Risk of Renal Complications Rises with Higher Urinary Oxalate Levels: Reduction of UOx Improves Renal Outcomes Illustrative Diagram Sources: Robertson and Hughes, Scanning Microsc. 1993; Keddis Curr Opin Nephrol Hypertens. 2013; Robertson and Peacock, Nephron. 1980; Milliner, Kidney Int. 2006; Curha
Slide 10: Allena Initially Targeting Enteric Hyperoxaluria Patients with Malabsorptive GI Diseases and Kidney Stones
Allena Initially Targeting Enteric Hyperoxaluria Patients with Underlying Malabsorptive GI Diseases and Kidney Stones 4-year progression of disease 4.4M Estimated Patients with GI Malabsorptive Conditions with No Prior Kidney Stones or CKD Patients potentially at risk for enteric hyperoxaluria1 Kidn
Slide 11: The Patient Journey for Severe Hyperoxaluria Patients
The Patient Journey for Severe Hyperoxaluria Patients Can Include Complex Specialty Care with Progressive Disease Strong Patient Advocacy: The Kidney Health Initiative project brings together patients, clinicians, industry and the FDA to evaluate potential endpoints for future clinical trials in ent
Slide 12: Reloxaliase for the Treatment of Hyperoxaluria
Reloxaliase for the Treatment of Hyperoxaluria
Slide 13: Clinical and Regulatory Progression of Reloxaliase (ALLN-177)
Clinical and Regulatory Progression of Reloxaliase (ALLN-177) Preclinical Ph 1 Healthy Volunteers Ph 2 Open Label Ph 2 Randomized Controlled Ph 3 Randomized Controlled ✓ ✓ ✓ ✓ Initiated 1Q 2018 and 4Q 2018 Progressive Increase in Enzyme Activity Porcine Rhubarb Model Presented at AUA 2016 Porcine We
Slide 14: Study 713: Substantially Greater Reloxaliase Treatment Response in Enteric Population
Study 713: Substantially Greater Reloxaliase Treatment Response in Enteric Population 1. Beyond the primary endpoint analysis, all p-values are descriptive. Overall (n=67) Enteric (n=18) Key Endpoints: Reloxaliase vs. placebo ∆ p-value ∆ p-value Change in UOx (mg/24h) from baseline to week 4 -6.35 m
Slide 15: Study 713: Substantially Greater Reloxaliase Treatment Response in Enteric Population
Study 713: Substantially Greater Reloxaliase Treatment Response in Enteric Population *Beyond the primary endpoint analysis, all p-values are descriptive. Enteric Reloxaliase Enteric Placebo Change in TWA Urinary Oxalate (mg/24h) Baseline Urinary Oxalate (mg/24h) Change in TWA UOx Excretion vs. Base
Slide 16: Reloxaliase Generally Well-Tolerated in Clinical Trials to Date
Reloxaliase Generally Well-Tolerated in Clinical Trials to Date 1TEAE = Treatment emergent adverse events are defined as AEs with onset at the time of or following the first dose of treatment with study drug through 7 days after their last dose of study medication, or AEs starting before the start o
Slide 17: Phase 3 Program Incorporates Key Learnings from Phase 2
Phase 3 Program Incorporates Key Learnings from Phase 2 Phase 3 Program Phase 2 Program Identified Phase 3 Patient Population Identified Pivotal Endpoint Identified Phase 3 Trial Design ü Identified Key Secondary Endpoints Enteric hyperoxaluria is a rare disease without available treatment ü Percent
Slide 18: URIROX-1: Evaluate the Safety and Efficacy of Reloxaliase in Enteric Hyperoxaluria
URIROX-1: Evaluate the Safety and Efficacy of Reloxaliase in Patients with Enteric Hyperoxaluria Study Update: > 50% enrolled Pretreatment data on initial patient cohort demonstrates decreased variability from screening to baseline in 24h UOx No safety concerns identified in blinded data On target t
Slide 19: URIROX-2 Study Design
Randomization 1:1 n≈400 RCT follow-up for minimum of 2 years Patient Population: Patients with enteric hyperoxaluria UOx ≥50 mg/d, history of kidney stones and eGFR ≥30 prior to screening Randomization stratified by: bariatric surgery vs. other enteric condition Endpoints for UOx Biomarker: Primary:
Slide 20: Reloxaliase Pivotal Program in Enteric Hyperoxaluria
1H 2018 2H 2018 1H 2019 2H 2019 1H 2020 2H 2020 Reloxaliase Pivotal Program in Enteric Hyperoxaluria Incorporates Consistent Biomarker Endpoints in Both Phase 3 Trials Follow subjects for a minimum of 2 years for post approval confirmation URIROX-1 in Enteric HO RCT x 4 weeks n=~124 Topline Data URI
Slide 21: Reloxaliase Additional Indications
Reloxaliase Additional Indications
Slide 22: Elevated Plasma Oxalate Increases Risk for CaOx Crystal Deposition
Elevated Plasma Oxalate Increases Risk for CaOx Crystal Deposition in the Kidney and Other Organ Systems Time and progression of disease Plasma Oxalate Level CKD 1 CKD 2 CKD 3 CKD 4 ESRD 0 15 30 45 2-5 µmol/L Normal range Systemic Oxalosis Dialysis Hyperoxalemia Study Population: Enteric Hyperoxalur
Slide 23: Study 206: Reloxaliase Treatment of Adult and Pediatric Patients with Primary or Enteric Hyperoxaluria
Study 206: Reloxaliase Treatment of Adult and Pediatric Patients with Primary or Enteric Hyperoxaluria and Advanced CKD ('Basket' Study) Study Design: Open-label study of subjects ≥ 12yrs in PH or EH w/ hyperoxalemia Key Endpoint: Change from baseline in POx and 24h UOx excretion Study Update: 8 enr
Slide 24: ALLN-346: Significant Opportunity in Gout Patients with Moderate-to-Severe CKD
ALLN-346: Significant Opportunity in Gout Patients with Moderate-to-Severe CKD Gout Market is Incompletely Served by Existing Therapies ~375,000 gout patients with moderate to severe CKD who have uncontrolled gout on urate lowering therapy (ULT)* Gout patients with renal impairment are not optimally
Slide 25: Execution of Clinical and Regulatory Milestones
Execution of Clinical and Regulatory Milestones YEAR TARGET MILESTONE STATUS 2018 1Q18 Initiate URIROX-1 ü 1Q18 Initiate Study 206, Phase 2 Study in PH and EH with Hyperoxalemia ü 2H18 Present ALLN-346 Animal Data New ü 2H18 Initiate URIROX-2 ü 2H18 Study 206 Interim Data Update ü 2019 1H19 File IND
Slide 26: Highlights – Pioneering Oral Enzyme Therapeutic Platform
Highlights – Pioneering Oral Enzyme Therapeutic Platform Significant Unmet Need in Oxalate and Urate Disorders Focused on rare and severe metabolic disorders that can cause kidney stones, damage the kidney, and potentially lead to CKD and ESRD No approved oxalate therapies; potential untapped multi-
Allena Pharmaceuticals — Investor Presentation (March 2019) on 6ix